证券代码：002273 股票简称：水晶光电 公告编号：（2025）063 号 浙江水晶光电科技股份有限公司 一、董事会会议召开情况 浙江水晶光电科技股份有限公司（以下简称"公司"）第七届董事会第三次会议通知于 2025 年 9 月 4 日以微信、电话和口头的形式发出。根据《董事会议事规则》的有关规定并 经全体董事一致同意,本次董事会会议豁免通知时限要求。会议于 2025 年 9 月 5 日上午 9:00 以通讯表决的方式召开。本次会议应出席董事 12 人，实际出席董事 12 人，会议由董事长李 夏云女士主持。本次会议的召开符合法律、法规、规章及公司章程的规定。 二、董事会会议审议情况 审议通过了《关于公司购买设备资产暨关联交易的议案》。 表决结果：关联董事林敏回避表决，同意 11 票，反对 0 票，弃权 0 票。 本次关联交易事项已经第七届董事会独立董事专门会议 2025 年第一次会议审议通过。 第七届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 董事会同意公司向关联方株式会社オプトラン购买镀膜设备，交易总金额为 33,600.00 ...

（记者 曾健辉） 截至发稿，水晶光电市值为361亿元。 每经头条（nbdtoutiao）——烤肉店里洗头、西湖边开面包店、进军高端酒店……海底捞"不务正业"背 后：子品牌存活率不足50% 每经AI快讯，水晶光电（SZ 002273，收盘价：25.98元）9月5日晚间发布公告称，公司第七届第三次董 事会会议于2025年9月5日以通讯表决的方式召开。会议审议了《关于公司购买设备资产暨关联交易的议 案》等文件。 2025年1至6月份，水晶光电的营业收入构成为：光学光电子行业占比92.2%，反光材料行业占比 6.21%，其他业务占比1.6%。 ...

智通财经APP讯，水晶光电(002273.SZ)公告，公司拟向公司之参股公司日本光驰购买镀膜设备，交易总 金额为3.36亿日元。日本光驰主要从事光学、触控面板等行业的镀膜设备及设备核心部件的研发、生产 和销售，精密镀膜设备是日本光驰的主要产品。 公告称，本次公司拟向日本光驰购买镀膜设备，有助于公司把握光学应用创新机遇，拓展光学产品线矩 阵，加快消费电子业务的转型升级步伐。 ...

Group 1 - The core viewpoint of the news is that Crystal Optoelectronics has shown significant stock performance and financial growth, with a notable increase in share price and market capitalization [1][2] - As of September 5, the stock price of Crystal Optoelectronics rose by 2.01% to 25.89 CNY per share, with a total market capitalization of 36.003 billion CNY [1] - The company has experienced a year-to-date stock price increase of 17.56%, with a 6.94% decline over the last five trading days, but a 24.29% increase over the last 20 days and a 37.27% increase over the last 60 days [1] Group 2 - Crystal Optoelectronics, established on August 2, 2002, and listed on September 19, 2008, specializes in optical imaging, film optical panels, automotive electronics (AR+), and reflective materials [2] - The company's revenue composition includes 84.20% from consumer electronics, 8.00% from automotive electronics (AR+), 6.21% from reflective materials, and 1.60% from other sources [2] - For the first half of 2025, Crystal Optoelectronics achieved a revenue of 3.02 billion CNY, representing a year-on-year growth of 13.77%, and a net profit attributable to shareholders of 501 million CNY, up 17.35% year-on-year [2] Group 3 - As of June 30, 2025, the top ten circulating shareholders of Crystal Optoelectronics include Hong Kong Central Clearing Limited, which holds 57.3245 million shares, a decrease of 53.4496 million shares from the previous period [3] - Southern CSI 500 ETF ranks as the fourth largest circulating shareholder with 20.6180 million shares, an increase of 2.8256 million shares [3] - In addition, Invesco Great Wall Quality Evergreen Mixed A has entered as a new shareholder, holding 15.8310 million shares [3]

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

2025 年 09 月 03 日 水晶光电 (002273) ——LCOS AR-HUD 获定点，加速布局阵列光波导 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2025 年 09 月 02 日 | | --- | --- | | 收盘价（元） | 25.70 | | 一年内最高/最低（元） | 29.16/15.10 | | 市净率 | 3.9 | | 股息率%（分红/股价） | 1.17 | | 流通 A 股市值（百万元） | 35,009 | | 上证指数/深证成指 | 3,858.13/12,553.84 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 06 月 30 日 | | | --- | --- | --- | | 每股净资产（元） | | 6.66 | | 资产负债率% | | 18.20 | | 总股本/流通 A 股（百万） | | 1,391/1,362 | | 流通 B 股/H 股（百万） | | -/- | 一年内股价与大盘对比走势： (8621)23297818× yanghy@swsresearch.com 09-02 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 浙江水晶光电科技股份有限公司2025年半年度权益分派实施公告 本公司及董事会全体人员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、根据《中华人民共和国公司法》《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第9号一一回购股份》等相关规定，上市公司回购专用账户中的股份，不享有股东会表决权、利润分 配、公积金转增股本、认购新股和可转换公司债券等权利。浙江水晶光电科技股份有限公司（以下简 称"公司"、"本公司"）回购专用证券账户中的14,732,555股不参与本次权益分派，本次实际参与分派的 股数为1,375,899,666股，实际分红总额为137,589,966.60元。 2、本次权益分派按公司总股本折算每10股现金分红=实际现金分红总额÷总股本 ×10=137,589,966.60÷1,390,632,221×10=0.989405元；本次权益分派实施后的除权除息参考价=除权除息 日的前一日收盘价-每股现金红利=除权除息日的前一日收盘价-0.0989405元/股。 证券代码：002273 股票简称：水晶 ...

本公司及董事会全体人员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 公司自律监管指引第 9 号——回购股份》等相关规定，上市公司回购专用账户中的股份，不 享有股东会表决权、利润分配、公积金转增股本、认购新股和可转换公司债券等权利。浙江 水晶光电科技股份有限公司（以下简称"公司"、"本公司"）回购专用证券账户中的 分红总额为 137,589,966.60 元。 考价=除权除息日的前一日收盘价-每股现金红利=除权除息日的前一日收盘价-0.0989405 元/股。 公司 2025 年半年度权益分派方案已经公司于 2025 年 5 月 8 日召开的 2024 年年度股东 大会授权，以及 2025 年 8 月 27 日召开的第七届董事会第二次会议审议通过，现将权益分派 事宜公告如下： 一、 股东大会审议通过的权益分派方案情况 会授权董事会决定 2025 年中期分红方案的议案》，同意在符合利润分配相关条件的前提下， 由董事会根据公司实际情况制定 2025 年度中期分红方案。本次半年度权益分派方案已经 预案为：以公司现有总股本 1,390,632,221 股扣除公司回购专户上已回购 ...

证券代码：002273 股票简称：水晶光电 公告编号：（2025）062 号 浙江水晶光电科技股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体人员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》《上市公司股份回购规则》《深圳证券交易所上市 公司自律监管指引第 9 号——回购股份》等相关规定，上市公司回购专用账户中的股份，不 享有股东会表决权、利润分配、公积金转增股本、认购新股和可转换公司债券等权利。浙江 水晶光电科技股份有限公司（以下简称"公司"、"本公司"）回购专用证券账户中的 14,732,555 股不参与本次权益分派，本次实际参与分派的股数为 1,375,899,666 股，实际 分红总额为 137,589,966.60 元。 2、本次权益分派按公司总股本折算每 10 股现金分红=实际现金分红总额÷总股本× 10=137,589,966.60÷1,390,632,221×10=0.989405 元；本次权益分派实施后的除权除息参 考价=除权除息日的前一日收盘价-每股现金红利=除权除息日的前一日收盘价-0.0989 ...

Group 1 - Since August, the A-share market has seen a significant increase in public fund research activity, with 163 public institutions participating in company research, covering 771 companies across 30 industries, and a total of 8,338 research instances, representing a month-on-month increase of 144.73% [1] Group 2 - The pharmaceutical and biotechnology sector was the most researched, with a total of 1,373 research instances covering 100 stocks, making it the highest focus area for public institutions in August; the electronics sector followed with 1,312 research instances covering 108 stocks [2] - Key companies in the pharmaceutical sector, such as Mindray Medical (300760), BeiGene, and Aibo Medical, were frequently researched, with a focus on innovative drug development, medical equipment updates, and the impact of centralized procurement policies [2] Group 3 - In the electronics sector, companies like Crystal Optoelectronics (002273), Unisoc (002049), and Industrial Fulian (601138) were core focuses due to their advancements in optical components and smart terminal manufacturing [2] - In the telecommunications sector, Tianfu Communication (300394) was the most researched company with 87 instances, focusing on the expansion of high-speed optical module capacity and the commercialization of silicon photonics technology [3] Group 4 - Public fund research activities showed a significant head effect, with 134 out of 163 participating institutions conducting more than 10 research instances, indicating a concentration of interest among top institutions [4] - Notable institutions included Bosera Fund with 200 research instances, followed by Harvest Fund (177 instances), Huaxia Fund (149 instances), and Guotai Fund (147 instances) [4] Group 5 - Research in August indicated a clear policy direction, with the pharmaceutical sector's rising interest linked to policy implementation, focusing on equipment updates and accelerated approval of innovative drugs [4] - The electronics sector maintained interest in cutting-edge fields such as optical technology and AI chips, despite a slight decrease in total research instances [4] - Increased research frequency in the machinery and power equipment sectors suggests institutional attention on inventory cycles bottoming out and a recovery in capital expenditure [4]